Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteriaPRNewsWire • 06/25/24
From Sci-Fi Dream to Market Maze: Eli Lilly's Weight-Loss Medication Faces HurdlesGuruFocus • 06/25/24
Medical-device makers ResMed and Inspire slump after Lilly's Zepbound trial shows benefits for sleep apneaMarket Watch • 06/24/24
Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — AgainInvestors Business Daily • 06/24/24
Weight-loss drug Zepbound resolves sleep apnea in up to 52% of patients, Lilly saysReuters • 06/21/24
Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolutionPRNewsWire • 06/21/24
Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the yearCNBC • 06/21/24
Eli Lilly (LLY) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research • 06/20/24